Alexander W. Rankin

Alexander W. Rankin

Auto-generated profile, based on publicly available information

Alexander W. Rankin

Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Blood
Verified
Journal Article
Open access
SSSara K. Silbert
Sara K. Silbert
ARAlexander W. Rankin
Alexander W. Rankin
CHChloe N. Hoang
Chloe N. Hoang
ASAlexandra Semchenkova
Alexandra Semchenkova
RMRegina M. Myers
Regina M. Myers
NSNirali N. Shah
Nirali N. Shah
Lineage switch (LS), defined as the immunophenotypic transformation of acute leukemia, has emerged as a mechanism of relapse after antigen-targeted immunotherapy, which is associated with dismal outcomes. Through an international collaborative effort, we identified cases of LS after a host of antigen-targeted therapies (eg, CD19, CD22, CD38, and CD7), described how LS was diagnosed, reviewed treatment approaches, and analyzed overall outcomes for this form of postimmunotherapy relapse. Collectively, 75 cases of LS were evaluated, including 53 (70.7%) cases of B-cell acute lymphoblastic leukemia (B-ALL) transforming to acute myeloid leukemia (AML), 17 (22.7%) cases of B-ALL transforming to mixed phenotypic acute leukemia (MPAL)/acute leukemias of ambiguous lineage (ALAL), and 5 (6.7%) cases of rare LS presentation (ie, T-cell ALL to AML). An additional 10 cases with incomplete changes in immunophenotype, referred to as “lineage drift” were also described. With a primary focus on the 70 cases of LS from B-ALL to AML or MPAL/ALAL, LS emerged at a median of 1.5 months (range, 0-36.5) after immunotherapy, with 81.4% presenting with LS within the first 6 months from the most proximal immunotherapy. Although most involved KMT2A rearrangements (n = 45, 64.3%), other rare cytogenetic and/or molecular alterations were uniquely observed. Treatment outcomes were generally poor, with remission rates of <40%. The median overall survival after LS diagnosis was 4.8 months. Outcomes were similarly poor for those with rare immunophenotypes of LS or lineage drift. This global initiative robustly categorizes lineage changes after immunotherapy and, through enhanced understanding, establishes a foundation for improving outcomes of LS.

13 December 2024 in Blood Advances
Verified
Journal Article
Open access
ISIsha Sahai
Isha Sahai
PBPaul Borgman
Paul Borgman
BYBonnie Yates
Bonnie Yates
SRSergio Rosenzweig
Sergio Rosenzweig
SRShakuntala Rampertaap
Shakuntala Rampertaap
NSNirali N. Shah
Nirali N. Shah

13 November 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ARAlexander W Rankin
Alexander W Rankin
CPCatherine Pham-Danis
Catherine Pham-Danis
ANAmanda J Novak
Amanda J Novak
EDEtienne Danis
Etienne Danis
TFTerry J Fry
Terry J Fry
MKM Eric Kohler
M Eric Kohler
Background: Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-modulated escape remains common. Multiple strategies to simultaneously target CD19 and CD22 have been able to reduce antigen-modulated escape but not completely eliminate relapse. A bicistronic CAR construct consisting of a CD19 CAR incorporating the CD28 costimulatory domain paired with a CD22 CAR incorporating a 4-1BB costimulatory domain (CD19xCD22) demonstrated superior preclinical activity compared with other configurations and is currently under clinical investigation ( NCT05098613 , NCT05442515 , NCT06559189 ). We hypothesized that simultaneous activation of CD28-containing and 4-1BB-containing CAR molecules not only allows for targeting of both antigens but creates a unique signal which enhances CAR T-cell function and efficacy. Methods: We tested CD19xCD22 CAR T-cells generated from primary human T-cells against NALM6 with wild-type expression of CD19 and CD22 (CD19+/CD22+) or CRISPR/Cas9 knockout of one or both antigens (CD19+/CD22−, CD19−/CD22+, CD19−/CD22−) to interrogate the effect of dual-CAR stimulation on T-cell function, signaling, and in vivo efficacy in xenograft models. Results: In vitro proliferation and cytokine production of CD19xCD22 CAR T-cells were primarily driven by activation of the CD19-28z CAR, however the CD22-BBz CAR drove equivalent cytotoxicity. Dual-CAR stimulation of CD19xCD22 CAR T-cells decreased leukemia relapse and improved survival in xenograft models. This increase in efficacy was associated with increased signaling through the phospholipase C-gamma 1 and nuclear factor of activated T-cells pathway after dual-CAR stimulation. Dual-CAR stimulation also led to decreased expression of markers associated with T-cell exhaustion in persistent CD19xCD22 CAR T-cells. Conclusions: Stimulation of both CAR molecules in a CD19xCD22 bicistronic CAR construct impacts downstream signaling events within the CAR T-cell and subsequently drives a more efficacious in vivo response with evidence of decreased exhaustion in persisting cells. These data suggest that bicistronic CAR platforms have the potential to not only target two antigens to prevent antigen-modulated escape but can be engineered to improve multiple facets of CAR T-cell biology, such as mitigating exhaustion, thereby overcoming multiple mechanisms known to drive relapse in current CAR T-cell therapies.

14 May 2026 in Blood Advances
Verified
Journal Article
Open access
ARAlexander W. Rankin
Alexander W. Rankin
RMRegina M. Myers
Regina M. Myers
ALAdam J. Lamble
Adam J. Lamble
EHEmily M. Hsieh
Emily M. Hsieh
HSHari Sankaran
Hari Sankaran
SRSusan R. Rheingold
Susan R. Rheingold
CD19 chimeric antigen receptor T cells (CD19-CAR) are effective at eradicating bone marrow (BM) B-cell acute lymphoblastic leukemia (B-ALL), but efficacy data for the treatment of extramedullary leukemia are lacking. We conducted a multisite, retrospective review of 308 children and young adults who received CD19-CAR and report efficacy in patients with active central nervous system (CNS) disease (CNS cohort, n = 36), active non-CNS extramedullary disease (EMD; n = 21), or isolated BM disease (iBM; n = 251) at infusion. The overall survival (OS) at 24 months in the iBM, EMD, and CNS cohorts was 71.5% (95% confidence interval [CI], 66.0-77.6), 66.7% (95% CI, 49.3-90.2), and 57.0% (95% CI, 42.6-76.3), respectively (P = .032); the corresponding event-free survival (EFS) was 51.8% (95% CI, 45.8-58.6), 45.8% (95% CI, 28.2-74.4), and 35.2% (95% CI, 22.4-55.3) (P = .035). All patients with isolated EMD (n = 5) achieved complete response and did not relapse. Eight patients (80%) with isolated CNS disease (n = 10) had clearing of the CNS, and 3 (37.5%) subsequently relapsed. Concurrent EMD or CNS disease with high BM disease burden (HD) was associated with inferior outcomes when compared with low BM disease burden (LD) in terms of OS (EMD-HD, 41.7% vs EMD-LD, 100%; P = .005; CNS-HD, 33.3% vs CNS-LD, 92.3%; P = .001) and EFS (EMD-HD, 8.3% vs EMD-LD, 100%; P< .001; CNS-HD, 14.3% vs CNS-LD, 63.6%; P< .001). In summary, CD19-CAR may be an effective option for relapsed/refractory B-ALL with active EMD or CNS disease, but concurrent HD predicts inferior outcomes, prompting consideration of enhanced preinfusion evaluation and treatment.

1 June 2026 in Hematology/Oncology and Stem Cell Therapy
Verified
Journal Article
Open access
ARAlexander W. Rankin
Alexander W. Rankin
HRHemalatha G. Rangarajan
Hemalatha G. Rangarajan
JSJoseph R. Stanek
Joseph R. Stanek
VPVinita Pai
Vinita Pai
RBRajinder P. Bajwa
Rajinder P. Bajwa
RARolla F. Abu-Arja
Rolla F. Abu-Arja
T-cell receptor alpha/beta+ T-cell/CD19+ B-cell (TCRαβ+/CD19+) depletion of allografts is increasingly used as a graft manipulation strategy for allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies. While outcomes using this approach are encouraging, limited data exist on associated costs and healthcare resource utilization (HRU). We conducted a single-center analysis comparing costs and HRU through HSCT day +100 in patients who received a TCRαβ+/CD19+-depleted (TCD) HSCT ( n = 20) to a contemporary cohort of patients who received a non-TCD HSCT ( n = 22). Median total inpatient costs through day +100 were $623,085 (interquartile range (IQR): $356,466–1,081,013] for TCD HSCTs and $451,876 (IQR: $313,601–787,351) for non-TCD HSCTs ( P = 0.234). Engraftment was rapid, with a median time to neutrophil engraftment of 10.0 versus 21.0 days ( P < 0.001) and platelet engraftment of 11.0 versus 22.0 days ( P < 0.001) for TCD and non-TCD HSCTs, respectively. Length of stay for the initial admission was shorter for patients who received a TCD HSCT (28.5 vs. 34.0 days, P < 0.001). Readmission through day +100 was required for 12 (60.0%) TCD patients and 6 (27.3%) non-TCD ( P = 0.060). In summary, while clinical outcomes were comparable, costs and HRU were not decreased after TCRαβ+/CD19+ depletion.

3 November 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
MSMark L. Solter
Mark L. Solter
YWYannan J Wang
Yannan J Wang
GLGrace Li
Grace Li
FHFahmida Haque
Fahmida Haque
BDBrynn B Duncan
Brynn B Duncan
NSNirali N Shah
Nirali N Shah